Supernus Pharmaceuticals Inc. got a green light from FDA to bring a second product to market for epilepsy patients Aug. 16. The Rockville, Md.-based company will be launching the once-daily extended release pill, Trokendi XR, before the end of the third quarter, CEO Jack Khattar said.
Trokendi XR is an extended-release version of topiramate, the generic drug that originally was sold under the brand name Topamax...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?